ArticleBMC cancer2025
Increased risk of nonalcoholic fatty liver disease in patients with thyroid cancer: a nationwide cohort study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven that patients with thyroid cancer experience several metabolic disorders, it is inferred that these patients have an elevated risk of non-alcoholic fatty liver disease (NAFLD). However, large-scale studies on this topic are lacking. This study aimed to elucidate the association between thyroid cancer and NAFLD.
methodsWe used data from the Korean National Health Insurance Service Sample Cohort. A total of 1,407 patients with thyroid cancer and 4,221 matched controls were included following the exclusion process and propensity score matching at a ratio of 1:3. We analyzed hazard ratio, risk factors for NAFLD.
resultsThe study revealed an increased risk of NAFLD (HR 2.28; 95% CI 1.69-3.10; P < 0.001) in patients with thyroid cancer. Thyroid cancer patients exhibited a higher risk of NAFLD when they had no regular exercise (HR 2.41; 95% CI 1.75-3.32). Moreover, body mass index (BMI) and levothyroxine dosage have been identified as potential critical factors for the development of NAFLD in patients with thyroid cancer.
conclusionThe incidence rate of NAFLD was higher in patients with thyroid cancer than in the controls. Healthcare professionals should consider regular physical activity, BMI, and cumulative levothyroxine dosage when managing patients with thyroid cancer to mitigate the incidence of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.